- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Marksans Pharma Limited — Updates, 19-05-2025: Press Release
19-05-2025 | 01:34 pm
19-05-2025 | 01:34 pm
Marksans Pharma’s UK subsidiary, Relonchem, received Marketing Authorization for Sennosides 7.5 mg Tablets, expanding its UK product portfolio. This approval supports potential revenue growth in gastroenterological therapies and reinforces Marksans’ strategy to strengthen its global generic pharma presence through manufacturing and regulatory gains.
No comments yet. Be the first to comment!